Target Name: FAM83H antisense RNA 1 (head to head)
NCBI ID: G100128338
Review Report on FAM83H antisense RNA 1 (head to head) Target / Biomarker Content of Review Report on FAM83H antisense RNA 1 (head to head) Target / Biomarker
FAM83H antisense RNA 1 (head to head)
Other Name(s): FAM83H-AS1

Introduction to FAM83H antisense RNA 1 (head to head), A Potential Drug Target

FAM83H antisense RNA 1 (head to head), also known as FAM83H-AS1, is a non-coding RNA molecule that has recently gained attention in the field of biomedical research. This article explores the potential of FAM83H-AS1 as a drug target or biomarker, shedding light on its role in various diseases and its potential therapeutic implications.

FAM83H-AS1: An Overview

FAM83H-AS1 is transcribed from the opposite strand of the gene FAM83H, resulting in a head-to-head gene organization with FAM83H. This non-coding RNA molecule is predominantly localized in the nucleus and has been found to be dysregulated in several human diseases.

Role in Cancer

One of the most studied aspects of FAM83H-AS1 is its involvement in cancer. Multiple studies have shown that FAM83H-AS1 is upregulated in various cancer types, including gastric cancer, hepatocellular carcinoma, and colorectal cancer. Higher expression levels of FAM83H-AS1 have been associated with tumor progression, metastasis, and poor prognosis in cancer patients. These findings suggest that FAM83H-AS1 could serve as a potential biomarker for cancer diagnosis and prognosis.

Biomarker Potential

The dysregulation of FAM83H-AS1 in various diseases, particularly cancer, indicates its potential as a valuable biomarker. The altered expression of this non-coding RNA molecule can be detected in various body fluids, such as blood, saliva, and urine, making it a promising candidate for non-invasive diagnostic methods. Researchers have been exploring the use of FAM83H-AS1 expression levels as a biomarker to detect early-stage cancer, monitor treatment response, and predict patient outcomes.

Mechanism of Action

The precise mechanism of action of FAM83H-AS1 is still under investigation, but emerging evidence suggests its involvement in multiple cellular processes. FAM83H-AS1 has been shown to regulate gene expression by interacting with chromatin remodeling complexes and modulating DNA methylation patterns. Additionally, it can act as a sponge for microRNAs, thereby indirectly affecting the expression of various target genes. The diverse roles of FAM83H-AS1 in cellular processes suggest its potential as a therapeutic target.

Therapeutic Implications

Given its dysregulation in diseases, targeting FAM83H-AS1 holds potential for therapeutic intervention. Multiple studies have explored the use of antisense oligonucleotides (ASOs) to specifically inhibit the expression of FAM83H-AS1. In preclinical models, these ASOs have demonstrated promising efficacy in reducing tumor growth and enhancing sensitivity to chemotherapy. Furthermore, combination therapies involving FAM83H-AS1 targeting and conventional treatments have shown synergistic effects.

Challenges and Future Directions

Despite the exciting therapeutic prospects of targeting FAM83H-AS1, several challenges need to be addressed. Delivery of ASOs to the target tissues or cells remains a significant hurdle, as they need to bypass numerous biological barriers. Moreover, off-target effects and potential toxicity of ASOs require thorough investigation. Additionally, the clinical validation of FAM83H-AS1 as a biomarker requires large-scale studies in diverse patient populations.


FAM83H antisense RNA 1 (head to head) has emerged as a potential drug target and biomarker in various diseases, particularly cancer. Its dysregulation and involvement in critical cellular processes make it an attractive therapeutic target. Additionally, the ease of detection in body fluids suggests its potential as a non-invasive biomarker for disease diagnosis and prognosis. Further research is needed to overcome the challenges associated with target delivery and validation in clinical settings. Nonetheless, FAM83H-AS1 holds significant promise in improving disease management and patient outcomes.

Protein Name: FAM83H Antisense RNA 1 (head To Head)

The "FAM83H antisense RNA 1 (head to head) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM83H antisense RNA 1 (head to head) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

FAM85A | FAM85B | FAM86B1 | FAM86B2 | FAM86B2-DT | FAM86B3P | FAM86C1P | FAM86C2P | FAM86DP | FAM86EP | FAM86FP | FAM86HP | FAM86JP | FAM86KP | FAM86MP | FAM87A | FAM87B | FAM88C | FAM88D | FAM88E | FAM88F | FAM89A | FAM89B | FAM8A1 | FAM90A1 | FAM90A10 | FAM90A11P | FAM90A13P | FAM90A14 | FAM90A18 | FAM90A19 | FAM90A20P | FAM90A25P | FAM90A26 | FAM90A27P | FAM90A2P | FAM90A5P | FAM90A6P | FAM90A7 | FAM91A1 | FAM95A | FAM95B1 | FAM95C | FAM98A | FAM98B | FAM98C | FAM99A | FAM99B | FAM9A | FAM9B | FAM9C | FAN1 | FANCA | FANCB | FANCC | FANCD2 | FANCD2OS | FANCE | FANCF | FANCG | FANCI | FANCL | FANCM | Fanconi anemia complex | FANK1 | FAP | FAR1 | FAR2 | FAR2P1 | FAR2P2 | FARP1 | FARP2 | FARS2 | FARS2-AS1 | FARSA | FARSB | FAS | FAS-AS1 | FASLG | FASN | FASTK | FASTKD1 | FASTKD2 | FASTKD3 | FASTKD5 | FAT1 | FAT2 | FAT3 | FAT4 | FATE1 | Fatty Acid Binding Protein | Fatty acid desaturase | FAU | FAUP1 | FAUP4 | FAXC | FAXDC2 | FBF1 | FBH1 | FBL